Review ArticlesAdvances in the Genetics and Biology of Pancreatic CancerAguirre, Andrew J. MD, PhD*; Collisson, Eric A. MD†Author Information From the *Dana-Farber Cancer Institute, Boston MA; and †Helen Diller Comprehensive Cancer Center, Department of Medicine, University of California San Francisco, San Francisco, CA. Conflicts of Interest and Source of Funding: E.A.C. is supported by grants from the National Institutes of Health, NCI (CA0109029, P0513423, CA178015), and US Department of Defense (W81XWH-16-1-0471). A.J.A. is supported by the Hope Funds for Cancer Research, the Doris Duke Charitable Foundation, Dana-Farber Cancer Institute Hale Center for Pancreatic Cancer (P50CA127003), and The Harvard Clinical and Translational Science Center (UL1 TR001102). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Eric A. Collisson, MD, Helen Diller Comprehensive Cancer Center, Department of Medicine, University of California San Francisco, 1450 3rd St, San Francisco, CA 94143. E-mail: [email protected]. The Cancer Journal: 11/12 2017 - Volume 23 - Issue 6 - p 315-320 doi: 10.1097/PPO.0000000000000286 Buy Metrics Abstract Pancreatic ductal adenocarcinoma (PDA) remains one of the most devastating diagnoses in modern medicine. While the clinical management of the disease has improved, the complex biologic underpinnings of PDA enable both its aggressive nature and slow clinical translational progress. In this review, we provide an overview of the key features of PDA genetics and biology, highlighting translational challenges and providing a framework for improved diagnostic and therapeutic approaches. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.